ALK and rheumatoid arthritis: Four reported RA patients treated with MTX or MTX and Janus kinase inhibitors suffered from sALCL and EBV+ CD30+ large-cell PTCL, and the three ALK− patients died of the disease within months, while the remaining patient with ALK+ sALCL is alive at 24 months [7, 11, 12, 22].